Aptevo Therapeutics Inc. Cash And Cash Equivalents At Carrying Value

• Aptevo Therapeutics Inc. showed an increase of +148.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Aptevo Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: $3.48 million | Q1 2016: $3.07 million | Q2 2016: $5.50 million | Q3 2016: $10.89 million | Q1 2017: $14.01 million | Q2 2017: $22.27 million | Q3 2017: $75.83 million | Q1 2018: $11.83 million | Q2 2018: $7.23 million | Q3 2018: $28.45 million | Q1 2019: $37.01 million | Q2 2019: $20.96 million | Q3 2019: $17.68 million | Q1 2020: $12.26 million | Q2 2020: $7.60 million | Q3 2020: $24.94 million | Q1 2021: $57.52 million | Q2 2021: $60.39 million | Q3 2021: $52.12 million | Q1 2022: $34.99 million | Q2 2022: $29.43 million | Q3 2022: $22.15 million | Q1 2023: $25.33 million | Q2 2023: $21.01 million | Q3 2023: $19.11 million | Q1 2024: $10.25 million | Q2 2024: $8.07 million | Q3 2024: $7.75 million | Q1 2025: $2.14 million | Q2 2025: $9.41 million | Q3 2025: $21.06 million.
• Over the full 12 years of available data (2014 to 2025), Aptevo Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 501.7%.
• Historical annual values: Fiscal year 2025: $21.62 million | Fiscal year 2024: $8.71 million | Fiscal year 2023: $16.90 million | Fiscal year 2022: $22.64 million | Fiscal year 2021: $45.04 million | Fiscal year 2020: $39.98 million | Fiscal year 2019: $12.45 million | Fiscal year 2018: $30.64 million | Fiscal year 2017: $7.10 million | Fiscal year 2016: $9.68 million | Fiscal year 2015: $4.64 million | Fiscal year 2014: $3.59 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026